UPDATE: Eventually Valeant (VRX) Fundamentals Will Matter Again - UBS

Valeant's (VRX) Price Target Reduced to $160 at TD Securities

TD Securities maintained a Buy rating on Valeant Pharmaceuticals (NYSE: VRX) but lowered its price target to $160.00 (from $260.00). Analyst Lennox Gibbs lowered Q4 EPS to $3.74 (from $4.11) and FY EPS to $16.16 (from $16.84) to reflect the business disruptions triggered by the discontinuation of its Philidor... More

Valeant Pharma (VRX) to Employ Drug Discounting Strategy in Effort to 'Protect Volume'

Valeant Pharma (NYSE: VRX) will be using an old business tactic as it looks to retain customers following recent controversial headlines surrounding the company:... More

Valeant (VRX) 'Conservative Base Case' Suggests 109% Upside - Nomura

Nomura Securities analyst Shibani Malhotra lowered her price target on Valeant Pharmaceuticals (NYSE: VRX) to $175.00 (from $220.00) but reiterated a Buy rating as her "Conservative Base Case" suggest 109% upside to current levels.

While the call did not address all our outstanding questions; however,... More

JPMorgan Cuts PT on Valeant (VRX) to $225

JPMorgan trims its price target on Valeant Pharma (NYSE: VRX) from $265 down to $225. The firm maintained its Overweight rating on Valeant

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Philidor Rx Disappointed Relationship with Valeant (VRX) Has Ended

Philidor Rx said in a statement:

We have valued our close working relationship with Valeant (NYSE: VRX) and are deeply disappointed that is has come to an end. It is unfortunate that this outcome was influenced by market forces, media misperceptions, and inflammatory,... More

Valeant Pharma (VRX) Moves Solidly Into the Green, Erasing 7.5% Loss

Embattled Valeant Pharma (NYSE: VRX) has gone solidly positive territory mid-day after trading down as much as 7.5% earlier. Shares last traded at $85.63, up 0.3%. Upside is related to... More

Citron's Left Says Valeant Pharma (VRX) Short 'Significantly Scaled-Down' from Initial Position

Citron's Andrew Left says short in Valeant Pharma (NYSE: VRX) is "significantly scaled down" from where it initially was.

Mallinckrodt (MNK) is not Valeant Pharma (VRX) 'it's worse' - Left

Mallinckrodt (NYSE: MNK) is not Valeant Pharma (NYSE: VRX), "it's worse", Citron Research's Andrew Left says

Streetinsider.com's Hot Lunchtime Reads 11/10: (VRX) (DE) (ETFC) (AAPL)

The following is a list of notable articles to help get you through the lunch hour:Deere & Co. (DE) Dips as USDA Lifts Corn, Soybean Crop Estimates ->... More

BMO 'Incrementally Positive' on Valeant (VRX) Following Conf. Call; Still See N-T Headline Risk Affecting Shares

BMO Capital is out with commentary on Valeant Pharma (NYSE: VRX) following today's conference call.

Analyst Alex Arfaei said the firm is incrementally positive on Valeant following the event. The analyst believes management provided good commentary about their near-term plans, and status of business operations. The focus now is on the remaining headline risk and execution in 2016.

Arfai sees near-term headline risk on Valeant as medium-to-high until the conclusion of the committee's investigation, at the earliest. The analyst commented, Valeants business is under high... More

Valeant Pharma (VRX) CEO Pearson Says Company 'is Going to Survive'

With its conference call today, Valeant Pharma (NYSE: VRX) said it doesn't have contingency plans if the stock keeps falling and it will sustain a short-term hit in its dermatology business.

CEO Michael Pearson also the company "is going to survive" and... More

Drugmaker Valeant to feel sting of closing controversial pharmacy

By Euan Rocha and Rod Nickel

TORONTO/WINNIPEG (Reuters) - Valeant Pharmaceuticals International Inc (NYSE: VRX) (NYSE: VRX) said on Tuesday its dermatology business would be hurt in the short term as it moves rapidly to sever ties with a controversial specialty pharmacy.

As of last week, Philidor Rx Services has stopped handling insurance claims for drugs and it will cease operations by the end of January, Valeant Chief Executive Officer Mike Pearson told investors and analysts on a conference call on Tuesday.

The call, however,... More